Medincell stock declines 2% following a rally sequence
The Montpellier-based biopharmaceutical company is losing momentum this Friday, retreating three days after a notable rebound that had propelled it among the best performers of the index. The decline occurs in a quasi-stable Paris market and pulls the security below two of its main moving averages, facing marked technical resistance.
A pullback that places Medincell back in the lower end of the SBF 120, amid persistent monthly pressure
Medincell is down 2.04% at €23.02 in trading, ranking among the strongest declines of the SBF 120 while the index evolves nearly balanced (+0.06%). This pullback erases part of Tuesday's rebound, which had offered the security a gain of nearly 4%. Over one month, pressure remains significant with a decline of 5.27%, while three-month performance reaches -7.99%, reflecting a downward trend established since summer.
The week remains nonetheless slightly positive: +3.04% over seven days, thanks to Tuesday's movement. The CAC 40 for its part shows virtually no change in trading (+0.03%), which underscores that Medincell's movement is not following the general direction of the Paris market this Friday.
A price trapped below the 50-day MA following Teva clinical data at Psych Congress
On the technical indicators side, Medincell is trading above its 20-day MA at €22.72 (a difference of +1.32%), which constitutes short-term support, but remains significantly below its 50-day MA at €24.11 (-4.52%) and its 200-day MA at €24.91 (-7.59%). These two averages form technical resistance that hampers recovery attempts. The RSI at 54 is neutral, showing no oversold or overbought signals.
To provide context, Teva had presented at Psych Congress 2026 (September 15-19 in New Orleans) new clinical data on two treatments based on Medincell's BEPO technology, with an FDA decision expected by end of 2026 on long-acting olanzapine. The nearest technical resistance remains at €24.88, the level that the security will need to break through to change configuration, while the €21.40 support represents the zone to defend in case of a prolonged pullback.
